Trial site
IMA Clinical Research San Antonio
San Antonio, Texas 78229, United StatesNot linked to an institution yet
- 16running trials
- 2closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 22 trials
- Phase 11 trial
- Status
- Recruiting8 trials
- Active, not recruiting6 trials
- Completed2 trials
- Not yet recruiting2 trials
- Lead sponsor
- Eli Lilly and Company9 trials
- Boehringer Ingelheim6 trials
- Amgen1 trial
- Endogenex, Inc.1 trial
- Hoffmann-La Roche1 trial
Running trials
Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT07881458· Phase 3· Eli Lilly and Company· Source
Contact: Lisa Blair (principal investigator)
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579· Phase 3· Eli Lilly and Company· Source
Contact: Lisa Blair (principal investigator)
Active, not recruiting
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
NCT07662122· Phase 2· Boehringer Ingelheim· Source
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190· Phase 3· Eli Lilly and Company· Source
Contact: Priscilla Thomas (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· Phase 3· Eli Lilly and Company· Source
Contact: Priscilla Thomas (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600· Phase 3· Eli Lilly and Company· Source
Contact: Priscilla Thomas (principal investigator)
Active, not recruiting
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719· Phase 3· Eli Lilly and Company· Source
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Lisa Blair (principal investigator)
Recruiting
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
NCT07136012· Phase 3· Amgen· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391· Endogenex, Inc.· Source
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230· Phase 2· Boehringer Ingelheim· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error